THE DIAGNOSIS OF CMV PNEUMONITIS IN LUNG AND HEART-LUNG TRANSPLANT PATIENTS BY PCR COMPARED WITH TRADITIONAL LABORATORY CRITERIA

被引:38
作者
BUFFONE, GJ
FROST, A
SAMO, T
DEMMLER, GJ
CAGLE, PT
LAWRENCE, EC
机构
[1] METHODIST HOSP,HOUSTON,TX 77030
[2] STANFORD UNIV,MED CTR,STANFORD,CA 94305
[3] TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030
[4] TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030
[5] TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT PULM IMMUNOL,HOUSTON,TX 77030
关键词
D O I
10.1097/00007890-199308000-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Polymerase chain reaction (PCR) amplification of CMV DNA recovered from bronchial alveolar lavage (BAL) and peripheral blood samples was compared with tissue culture, cytology, and/or histology for the earlier detection of CMV pneumonitis in 12 recipients of single-lung or heart/lung transplants. In patients with confirmed CMV pneumonitis, cytological evidence of CMV disease in BAL samples was detected 38+/-14 days post-transplantation, while tissue culture and PCR-positive results were noted as early as 30+/-4.0 days and 18+/-4.6 days, respectively. While PCR was positive earlier than culture in a number of cases, culture-positive results were subsequently obtained in each case, consistent with earlier detection of viral replication by PCR as opposed to detection of latent virus. CMV was detected by PCR in 6 of 24 blood samples from patients with confirmed or suspected CMV pneumonitis, while results of all 24 blood samples were negative when assayed by tissue culture. PCR-based testing was more sensitive than traditional tests, allowing detection of viral replication earlier than tissue culture in the posttransplant period. PCR could provide a powerful means of monitoring the immunocompromised patients in whom preemptive therapeutic intervention for CMV disease is desirable.
引用
收藏
页码:342 / 347
页数:6
相关论文
共 21 条
[1]  
BUFFONE GJ, 1991, CLIN CHEM, V37, P1945
[2]  
BUHLES WC, 1988, REV INFECT DIS, V10, pS405
[3]  
CAGLE PT, 1989, MODERN PATHOL, V2, P65
[4]   PRIMER-MEDIATED ENZYMATIC AMPLIFICATION OF CYTOMEGALO-VIRUS (CMV) DNA - APPLICATION TO THE EARLY DIAGNOSIS OF CMV INFECTION IN MARROW TRANSPLANT RECIPIENTS [J].
CASSOL, SA ;
POON, MC ;
PAL, R ;
NAYLOR, MJ ;
CULVERJAMES, J ;
BOWEN, TJ ;
RUSSELL, JA ;
KRAWETZ, SA ;
PON, RT ;
HOAR, DI .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1109-1115
[5]  
EINSELE H, 1991, BLOOD, V77, P1104
[6]   POLYMERASE CHAIN-REACTION TO EVALUATE ANTIVIRAL THERAPY FOR CYTOMEGALOVIRUS DISEASE [J].
EINSELE, H ;
EHNINGER, G ;
STEIDLE, M ;
VALLBRACHT, A ;
MULLER, M ;
SCHMIDT, H ;
SAAL, JG ;
WALLER, HD ;
MULLER, CA .
LANCET, 1991, 338 (8776) :1170-1172
[7]   CYTOMEGALO-VIRUS PNEUMONIA AFTER BONE-MARROW TRANSPLANTATION SUCCESSFULLY TREATED WITH THE COMBINATION OF GANCICLOVIR AND HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN [J].
EMANUEL, D ;
CUNNINGHAM, I ;
JULESELYSEE, K ;
BROCHSTEIN, JA ;
KERNAN, NA ;
LAVER, J ;
STOVER, D ;
WHITE, DA ;
FELS, A ;
POLSKY, B ;
CASTROMALASPINA, H ;
PEPPARD, JR ;
BARTUS, P ;
HAMMERLING, U ;
OREILLY, RJ .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (10) :777-782
[8]   PULMONARY CONSIDERATIONS OF ORGAN-TRANSPLANTATION .3. [J].
ETTINGER, NA ;
TRULOCK, EP .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (02) :433-451
[9]   EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
MORI, M ;
GLEAVES, CA ;
DUMOND, C ;
CAYS, M ;
EBELING, DF ;
BUHLES, WC ;
DEARMOND, B ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607
[10]  
ICENOGLE T B, 1987, Journal of Heart Transplantation, V6, P199